NLS Pharmaceutics Ltd. Extraordinary Shareholders' Meeting Report - January 2025

Here are the key insights extracted from the provided section of the financial report for NLS Pharmaceutics Ltd.:

1. Document Type and Filing Information:

• The document is a Form 6-K, which is a report of a foreign private issuer.
• It is filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.
• The report is dated January 14, 2025, and is identified as Report No. 3 with commission file number 001-39957.

2. Extraordinary Shareholders' Meeting:

• An extraordinary shareholders' meeting was held on January 14, 2025.
• A quorum was present at the meeting.
• Shareholders approved all agenda items discussed during the meeting.

3. Incorporation by Reference:

• The report is incorporated by reference into the Registrant’s Registration Statements on Form F-3, which includes multiple file numbers (333-282788, 333-262489, 333-268690, and 333-269220).
• This indicates that the information in this report is part of the official filings and could be relevant for investors and stakeholders.

4. Company Information:

• The report pertains to NLS Pharmaceutics Ltd., which has its principal executive offices located at The Circle 6, 8058 Zurich, Switzerland.

5. Signatures Section:

• The report was signed by Alexander Zwyer, the Chief Executive Officer of NLS Pharmaceutics Ltd., on the same date as the meeting (January 14, 2025).

Overall, this section primarily reports the results of the extraordinary shareholders' meeting, confirming that all items were approved, and it provides relevant regulatory filing information that is crucial for compliance and investor awareness.